NTC and I-MED Pharma form strategic partnership to bring the leading HA-based dry eye ointment to the United States market

  • Dec 15, 2021

NTC Srl and I-MED Pharma Inc announced today that I-DEFENSE®, a long-lasting, lubricating ointment containing 0.4% sodium hyaluronate indicated for the relief of dry eyes and lagophthalmos symptoms has been successfully registered with the U.S.A. Food and Drug Administration. It is the first European NTC medical device product for ophthalmic use approved in the U.S.A.

NTC and Aspen announce SAHPRA positive outcome for the fixed dose combination of levofloxacin and dexamethasone multidose eye drops

  • Nov 24, 2021

NTC granted the license and commercialisation rights of its patented research and development product to Aspen for South Africa and other African countries, and has provided full technical and regulatory support to Aspen which has secured market authorisation for the product in South Africa.

NTC and STADA announce commercial partnership for portfolio of ophthalmic products in the MENA region

  • Sep 07, 2021

NTC, international pharmaceutical company headquartered in Milan, Italy, and STADA, a global leading pharmaceutical player with significant presence in the Middle East and North Africa (MENA) region, today announce a commercial ophthalmic partnership.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. READ MORE